Effect of Papilozumib Oral on Vaginal and Intestinal Microbiota in HPV-Positive Women

This open-label, single-group study evaluated the effects of a 3-month oral synbiotic dietary supplement on vaginal and intestinal microbiota in women with a positive human papillomavirus (HPV) test. Vaginal and intestinal microbiota were assessed at baseline and after 3 months of supplementation. Secondary assessments included HPV clearance, vaginal health, safety and tolerability, and treatment adherence.

NCT Number	NCT07755566
Lead Sponsor	Hifas da Terra S.L. Collaborators: Eurofins
Conditions	Papillomavirus Infections
Enrollment	21 participants
Start Date	2023-05-05
Primary Completion	2024-05-30 (estimated)
Study Completion	2024-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-10